This follows a move by Bayer to import Ultravist with non-U.S. labeling also to address pandemic-related shortages of iodine-containing contrast media used in imaging procedures.
The FDA has allowed Bracco Diagnostics to import Iomeron (iomeprol injection) into the United States to address the ongoing iodinated contrast media shortage. Iodinated contrast media are contrast agents that contain iodine atoms used for x-ray-based imaging such as computed tomography (CT).
Iomeron is an iodinated contrast medium for intravascular use in adults in various imaging procedures. It is currently registered in more than 50 countries in Europe and Asia, but it is not approved for use in the United States. Iomeron will be temporarily available in the United States at the end of August 2022. It is manufactured at two Bracco locations: BIPSO in Germany and Patheon in Italy.
The FDA is allowing this importation to address shortages of GE Healthcare’s Omnipaque (iohexol injection) and Visipaque (iodixanol injection), as well as Bayer’s Ultravist (iopromide injection).
GE Healthcare, in particular, has experienced challenges related to manufacturing Omnipaque and Visipaque because of the COVID-19 pandemic. The company’s plant is located in Shanghai, which has experienced closures related to China’s COVID-19 policies. This has created supply disruption. In a statement issued July 15, 2022, the company said the Shanghai facility is operating at full capacity but indicated that there will continue to be reduced availability of its iodinated contrast media.
The supply of Bayer’s Ultravist has also experienced disruption because of the pandemic. In June 2022, the company announced it had received approval from the FDA to import Ultravist with non-U.S. labeling. The product to be imported is manufactured at the same site in Germany as the U.S.-label Ultravist, but doesn’t include FDA approved labeling and the package inserts may differ. The bar codes are also different, the company indicated.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More